King Wealth Management Group’s TG Therapeutics TGTX Stock Holding History

King Wealth Management Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,803	Closed	-$223K	–	156
2023 Q1	$223K	Sell	14,803 -9,622	-39%	-$146K	0.05%	129
2022 Q4	$289K	Buy	24,425 +625	+3%	+$4.54K	0.07%	111
2022 Q3	$141K	Sell	23,800 -5,000	-17%	-$32.8K	0.04%	144
2022 Q2	$122K	Hold	28,800	–	–	0.03%	153
2022 Q1	$274K	Hold	28,800	–	–	0.05%	141
2021 Q4	$547K	Hold	28,800	–	–	0.1%	99
2021 Q3	$958K	Sell	28,800 -10,000	-26%	-$309K	0.2%	67
2021 Q2	$1.5M	Sell	38,800 -10,000	-20%	-$393K	0.31%	50
2021 Q1	$2.35M	Hold	48,800	–	–	0.53%	35
2020 Q4	$2.54M	Hold	48,800	–	–	0.6%	33
2020 Q3	$1.31M	Hold	48,800	–	–	0.34%	40
2020 Q2	$951K	Hold	48,800	–	–	0.28%	54
2020 Q1	$480K	Hold	48,800	–	–	0.21%	64
2019 Q4	$542K	Buy	48,800 +10,000	+26%	+$76K	0.14%	66
2019 Q3	$218K	Hold	38,800	–	–	0.06%	131
2019 Q2	$336K	Sell	38,800 -18,500	-32%	-$140K	0.1%	91
2019 Q1	$461K	Buy	57,300 +21,700	+61%	+$117K	0.14%	72
2018 Q4	$146K	Buy	+35,600	New	+$177K	0.05%	123

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

King Wealth Management Group's TGTX Position: Q2 2023 in Review

King Wealth Management Group sold out of TG Therapeutics (TGTX) in Q2 2023, closing a stake of 14,803 shares — an estimated $223K sold.

King Wealth Management Group first reported a position in TGTX in Q4 2018 and held it in 18 quarters. The position peaked at $2.54M in Q4 2020. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

King Wealth Management Group reported no remaining TG Therapeutics position as of Q2 2023 after selling out during the quarter.
King Wealth Management Group sold 14,803 TG Therapeutics shares in Q2 2023, an estimated $223K.
King Wealth Management Group first reported a position in TG Therapeutics in Q4 2018 and held it in 18 quarters.
King Wealth Management Group's TG Therapeutics position peaked at $2.54M in Q4 2020.
244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on King Wealth Management Group's 13F filing for Q2 2023, filed 10 Aug 2023.